Lung Cancer Screening Guideline

Background ............................................................................................................................................. 2
Prevention ............................................................................................................................................... 2
Screening Recommendations ................................................................................................................. 2
Shared Decision Making .......................................................................................................................... 3
Pulmonary Nodule Workup/Referrals ..................................................................................................... 4
Evidence Summary ................................................................................................................................... 5
References .............................................................................................................................................. 5
Guideline Development Process and Team ........................................................................................... 6

Last guideline approval: November 2014

Guidelines are systematically developed statements to assist patients and providers in choosing appropriate health care for specific clinical conditions. While guidelines are useful aids to assist providers in determining appropriate practices for many patients with specific clinical problems or prevention issues, guidelines are not meant to replace the clinical judgment of the individual provider or establish a standard of care. The recommendations contained in the guidelines may not be appropriate for use in all circumstances. The inclusion of a recommendation in a guideline does not imply coverage. A decision to adopt any particular recommendation must be made by the provider in light of the circumstances presented by the individual patient.
Background

Lung cancer is the third most common cancer and the leading cause of cancer death in the United States. According to the U.S. Preventive Services Task Force (USPSTF), nearly 90% of individuals with lung cancer die of the disease. However, when detected at an early stage, non–small cell lung cancer (NSCLC) has a better prognosis and can be treated with surgical resection. (The majority of lung cancer cases are NSCLC.)

The most important risk factor for lung cancer is smoking, which results in approximately 85% of all U.S. lung cancer cases. The incidence of lung cancer increases with age, occurring most commonly in individuals aged 55 years or older. Increasing age and cumulative exposure to tobacco smoke are the two factors most strongly associated with the occurrence of lung cancer.

The USPSTF found adequate evidence that annual screening with low-dose computed tomography (LDCT) in current and former smokers aged 55 to 79 years who have significant cumulative tobacco smoke exposure can prevent a substantial number of lung cancer deaths. LDCT has greater sensitivity for detecting early-stage cancer than chest X-ray and sputum cytology; however, it also has a very high rate of false positives (about 95%). For the benefits to outweigh the harms, screening needs to be limited those who are at the highest risk for lung cancer.

Prevention

While screening with LDCT can prevent some lung cancer deaths, it is important to emphasize to patients that the single most effective way to reduce lung cancer risk is smoking cessation. For every year patients don’t smoke, their risk for lung cancer goes down.

For recommended interventions to help patients quit smoking, see the Tobacco Use Guideline.

Screening Recommendations

<table>
<thead>
<tr>
<th>Screening: Key points for discussion</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Lung cancer screening is not a substitute for smoking cessation.</td>
</tr>
<tr>
<td>• Not all people who may be at risk for lung cancer will benefit from screening.</td>
</tr>
<tr>
<td>• Screening should be limited to those at highest risk for lung cancer, for whom the benefits are more likely to outweigh the harms.</td>
</tr>
</tbody>
</table>

Note: The screening criteria, as well as diagnosis codes, progress notes, LDCT order, and patient instructions are included in the Epic SmartSet Low Dose CT- Lung Cancer Screening.

Initiation

Ages 55 through 74: Annual screening for lung cancer with low-dose computed tomography is recommended for patients who meet all three of the following criteria:

- Have at least a 30-year pack history, and
- Currently smoke or quit less than 15 years ago, and
- Have no significant comorbidities that would preclude surgical treatment or limit life expectancy.

For this group of patients, the number needed to screen (NNS) to prevent one lung cancer death is 320 (Patz 2014).

Ages 75 through 77: For patients who meet the above criteria, clinical judgment is recommended in deciding whether to initiate annual lung cancer screening with LDCT.

Ages 78 and over: Annual lung cancer screening with LDCT is not recommended.
Discontinuation
Discontinuation of lung cancer screening is recommended at 15 years following the patient’s quit date, or as appropriate for health status.

Things to consider before screening
Potential reasons to exclude patients from screening may include the following; use clinical judgment.

- Metallic implants or devices in the chest or back, such as pacemakers or Harrington fixation rods.
- Treatment for, or evidence of, any cancer other than nonmelanoma skin cancer or carcinoma in situ (with the exception of transitional cell carcinoma in situ or bladder carcinoma in situ) in the 5 years prior to eligibility assessment.
- History of lung cancer.
- Requirement for home oxygen supplementation.
- Unexplained weight loss of more than 15 pounds in the 12 months prior to eligibility assessment.
- Pneumonia or acute respiratory infection treated with antibiotics in the 12 weeks prior to eligibility assessment.
- Chest CT examination in the 12 months prior to eligibility assessment.
- Patient is not a candidate for surgical treatment.

Shared Decision Making

<table>
<thead>
<tr>
<th>Advantages/benefits</th>
<th>Disadvantages/risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>For high-risk patients, screening can provide some hope for prevention of death from lung cancer by detecting lesions when they are most treatable.</td>
<td>95% false-positive rate, which may lead to anxiety and unnecessary follow-up tests and surgeries that pose risks to the patient.</td>
</tr>
<tr>
<td></td>
<td>Overdiagnosis: finding cases of cancer that may never have caused a problem for the patient and lead to treatment that is not needed and can be harmful.</td>
</tr>
<tr>
<td></td>
<td>Radiation from repeated LDCT tests can cause cancer in otherwise healthy people.</td>
</tr>
<tr>
<td></td>
<td>False-negative results.</td>
</tr>
</tbody>
</table>
Pulmonary Nodule Work-up/Referrals

Asymptomatic, high-risk patients who choose to be screened will undergo lung cancer screening with LDCT. The radiologist’s report will follow standardized LDCT reporting and management recommendations developed by the American College of Radiology (ACR) using the ACR Lung Imaging Reporting and Data System (Lung-RADS™). The Lung-RADS system was designed to reduce confusion in interpreting screening results by standardizing the language used to describe pulmonary nodules and by providing detailed, specific guidance for follow-up.

The radiologist’s report for the LDCT scan will include these recommendations tailored to each patient’s individual LDCT findings. The findings will be categorized depending on number, size and other nodule characteristics. Management and follow-up for patients will be based on category, as shown in Table 2.

For more information on nodule categorization by size and other characteristics, see the ACR website at www.acr.org/Quality-Safety/Resources/LungRADS.

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
<th>Probability of malignancy</th>
<th>Primary Care follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Incomplete</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>1</td>
<td>Negative</td>
<td>&lt; 1%</td>
<td>Continue annual screening with LDCT in 12 months.</td>
</tr>
<tr>
<td>2</td>
<td>Benign appearance or behavior</td>
<td>&lt; 1%</td>
<td>Continue annual screening with LDCT in 12 months.</td>
</tr>
<tr>
<td>3</td>
<td>Probably benign</td>
<td>1–2%</td>
<td>Repeat LDCT in 6 months.</td>
</tr>
</tbody>
</table>
| 4a, 4b, or 4x Suspicious | Findings for which additional diagnostic testing and/or tissue sampling is recommended. | 4a: 5–15%  
4b or 4x: > 15% | Refer to Pulmonology. |

Incidental findings

- Emphysema: Consider pulmonary function testing.
- Bronchiectasis or pulmonary fibrosis: Consider virtual consult with Pulmonary to review CT images.
- Aortic dilation: Consider virtual consult with Cardiology.
- Pericardial effusion: Consider echocardiogram for large pericardial effusion.
Evidence Summary

To develop the Lung Cancer Screening Guideline, Group Health has adapted the recommendations from the following national guidelines:

- American Lung Association Guidance on Lung Cancer Screening (2012)
- U.S. Preventive Services Task Force Recommendation Statement: Screening for Lung Cancer (USPSTF 2013)
- American Cancer Society Cancer Screening Guidelines (Wender 2013)
- American College of Chest Physicians Evidence-Based Clinical Practice Guidelines: Screening for lung cancer (Detterbeck 2013)
- American College of Chest Physicians Evidence-Based Clinical Practice Guidelines: Evaluation of individuals with pulmonary nodules (Gould 2013)
- Fleischner Society Statement: Recommendations for the management of subsolid pulmonary nodules detected at CT. (Naidich 2013)
- National Comprehensive Cancer Network Guidelines: Lung Cancer Screening (Wood 2014)

References


Guideline Development Process and Team

Development process
To develop the Lung Cancer Screening Guideline, Group Health adapted recommendations from externally developed evidence-based guidelines and/or recommendations of organizations that establish community standards. See the Evidence Summary and References section.

This edition of the guideline was approved for publication by the Guideline Oversight Group in November 2014.

Team
The Lung Cancer Screening Guideline development team included representatives from the following specialties: clinical informatics, family medicine, the Group Health Research Institute, oncology, pulmonology, and radiology.

Clinician lead: David Grossman, MD, MPH, Medical Director, Population and Purchaser Strategy, grossman.d@ghc.org

Guideline coordinator: Avra Cohen, MN, Clinical Improvement & Prevention, cohen.al@ghc.org

Fred Brodsky, MD, Clinical Informatics
Diana Buist, PhD, Group Health Research Institute
Eric Chen, MD, Oncology
Peter Chuang, MD, Pulmonology
Matt Fei, MD, Pulmonology
Quinn Jenkins, MPH, Clinical Epidemiologist, Clinical Improvement & Prevention
Robert Karl, MD, Radiology
Sarah Levy, MD, Assistant Medical Director, Primary Care
Priscilla Madsen, MD, Pulmonology
Robyn Mayfield, Patient Engagement Team, Clinical Improvement & Prevention
Jennifer Nazarko, Service Line Director
Marcy Parsons, Director, Regional Clinic Operations and Market Integration
Ann Stedronsky, Clinical Publications, Clinical Improvement & Prevention
Carolyn Wild, MD, Oncology

Acknowledgments
The guideline team would like to acknowledge the contributions of Bette Drescher, Matt Handley, Johanne Leblanc, Genevieve McGrann, Christie Randolph, Robert Winter and other members of the Lung Cancer Screening implementation team.

Disclosure of conflict of interest
Group Health Cooperative requires that team members participating on a guideline team disclose and resolve all potential conflicts of interest that arise from financial relationships between a guideline team member or guideline team member’s spouse or partner and any commercial interests or proprietary entity that provides or produces health care–related products and/or services relevant to the content of the guideline.

Team members listed above have disclosed that their participation on the Lung Cancer Screening Guideline team includes no promotion of any commercial products or services, and that they have no relationships with commercial entities to report.